Health-Medicine

PredictMedix: Value Meets Growth

Technology is different from every other sector by virtue of one important factor – it scales. Because technology is scaleable, firms penetrate international markets easily,

Read More »

I asked Twitter what tickers I should be writing about: Twitter had 35 ideas… here’s 6 of them

Ever get the feeling, looking at your watchlist, that you’re seeing the same thing over and over? That maybe there’s interesting stuff out there you just haven’t heard about yet? I put a simple question to Twitter today: “Give me a ticker symbol you think I should be writing about (limit one per person), three reasons you think it’s great, and one thing you’ll openly admit they need to do better.” I got 35. Gulp.

Read More »

Revive Therapeutics (RVV.C) warned about overhype, but up 26% on clinical trial news

Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts from certain folks wondering if that meant trouble for us – or them. It’s not a problem for us; our coverage has been appropriately even-handed.

Read More »

Did Aytu BioScience (AYTU.Q) just SpankChain the NASDAQ?

When a sector gets hot, small cap stocks can often get a bump by sidling up to the hot sector with a new product/idea/opportunity. When the dust clears, the intrinsic value of the new offering is typically deemed to be low. We saw it in 3D-printing, with Dung Beetle Treats. We saw it in weed with a $1 billion website that forgot to sell cannabis. We saw it in blockchain with a Cryptocoin for porno transactions.

Read More »

Shroom stocks go nuts: First movers SHRM, MMED, RVV up hard as gamblers gamble

Today was a day that daytraders have been looking forward to for some time; the day that shroom stocks finally gripped the road and took off. Mind Medicine (MMED.E) ripped 90% to $0.77 on the back of 15m shares traded, reminding anyone who’d listen that ex-Canopy CEO Bruce Linton and pretend billionaire Kevin O’Leary were on board. Champignon Brands (SHRM.C) zoomed 40% to $0.33 on a lot smaller market awareness spend byt a handy ticker, Roadman Investments (LITT.V) was up 30% to $0.065 being sucked along in the other two companies’ wake, and Revive Therapeutics (RVV.C) was up 81% to $0.10 on ripples caused by the rest.

Read More »

CloudMD (DOC.C): Perhaps this might be a good time to talk about investing in telemedicine

As happens whenever a global crisis hits, there are plenty of investors currently watching the global Coronavirus outbreak and looking to panic sell. There are also a few looking to capitalize on the opportunities found in potential doom. Like folks who buy gun stocks whenever a military conflict breaks out, or those who buy gold as a safe haven when the world’s leaders engage in a game of ‘Armageddon chicken.’ a pandemic brings about macroeconomic changes that can be utilised to make money.

Read More »

2020 Gravitas Securities Growth Conference lines up seriously interesting deals, even in weed

Respect where it’s due, I haven’t been to an investor conference in a long time where I came away interested in most of what I saw, let alone *everything* I saw, but this year’s Gravitas Securities Growth Conference lineup absolutely hit it out of the park. The GSGC isn’t the biggest show around, but they know how to turn out the playahs, and the only way you keep big money showing up is to be a little bit picky with what you offer them. Don’t waste anyone’s time and they’ll know it’s cool to return.

Read More »

Equity Guru Podcasts